Publications by authors named "R E CERRONI"
Background: Gastrointestinal dysfunction (GID) accompanies any phase of Parkinson's disease (PD), underlying differential clinical-pathological trajectories.
Objective: To investigate associations between GID and peripheral immune or neurodegeneration-related markers in PD.
Methods: One-hundred-and-fourteen patients (n = 55 de novo, DN; n = 59 middle-advanced, MA) completed the Gastrointestinal Dysfunction Scale for PD (GIDS-PD), and other motor and non-motor scales; paired measurement of amyloid-β42, amyloid-β42β/β40, total-tau, phosphorylated-181-tau, total α-synuclein CSF levels, albumin ratio, and peripheral blood cell count were collected.
Parkinson's disease (PD) epidemiology and clinical features are sexually dimorphic. However, there are no data based on EEG functional connectivity (FC). Likewise, the contribution of sex hormones on brain FC has never been evaluated.
View Article and Find Full Text PDFBackground: Rapid eye movement (REM) sleep behavior disorder (RBD) may precede motor symptoms in Parkinson's disease (PD) by years. According to a recent hypothesis, premotor RBD (pRBD) is a marker of the PD body-first subtype, where synucleinopathy originates from the peripheral autonomic nervous system. Conversely, in the brain-first subtype, pathology would arise in the brain.
View Article and Find Full Text PDFArticle Synopsis
- Sleep problems are common in Parkinson's disease (PD) and can seriously impact patients' quality of life, with the study focusing on the effects of monoamine oxidase-B inhibitors (MAOB-Is) on these disturbances.
- In a study of 45 PD patients with sleep issues, treatment with rasagiline and safinamide over four months showed improvements in motor function, with safinamide leading to better sleep quality and reduced movement disturbances.
- Safinamide not only alleviated motor symptoms but also improved both subjective and objective sleep measures, suggesting its dual action on the brain may benefit sleep health in PD patients.
The complexity and heterogeneity of PD necessitate advanced diagnostic and prognostic tools to elucidate its molecular mechanisms accurately. In this study, we addressed this challenge by conducting a pilot phospho-proteomic analysis of peripheral blood mononuclear cells (PBMCs) from idiopathic PD patients at varying disease stages to delineate the functional alterations occurring in these cells throughout the disease course and identify key molecules and pathways contributing to PD progression. By integrating clinical data with phospho-proteomic profiles across various PD stages, we identify potential stage-specific molecular signatures indicative of disease progression.
View Article and Find Full Text PDF